"Results of this proof-of-concept study represent an important first step toward developing and applying systemic targeted therapy in the clinic for patients who could for the first time derive ...
• Results of a preclinical, proof-of-concept study led by VHIO’s Stem Cells and Cancer Group demonstrate for the first time the promise of systemic targeted therapy in patients with pseudomyxoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results